Latest Us Expansion News

Page 4 of 32
Metallium has completed a 12-hour campaign using three Flash Joule Heating reactors to process platinum-group-metal-bearing catalytic converter material under reactive chlorination conditions. The milestone advances the company’s scale-up program, but recovery results, product economics and feedstock grades remain unverified.
Victor Sage
Victor Sage
1 Oct 2026
Peak Processing delivered its first positive Group EBITDA quarter in FY2026, but the turnaround remains financially fragile. The ASX-listed THC beverage manufacturer reported a $7.8 million statutory loss, negative operating cash flow and an explicit material uncertainty over its ability to continue as a going concern.
Victor Sage
Victor Sage
30 Sept 2026
SQX Resources Limited (ASX:SQX) has emerged from a transformational year with two advanced US gold projects, broad shallow mineralisation at Red Bird and exceptional underground assays at Williams. The exploration gains came alongside a $1.83 million loss, falling cash and a further $2.47 million capital raising completed after year-end.
Maxwell Dee
Maxwell Dee
30 Sept 2026
Vitrafy has added US blood network Versiti to its cryopreservation development programme, with the partnership focused on no-wash platelet preservation and regulatory verification. The deal strengthens the company’s institutional network, but initially generates no revenue and remains subject to US regulatory requirements.
Victor Sage
Victor Sage
30 Sept 2026
RMA Global has replaced its chief executive and moved to a new chair as it targets a simpler, faster and more profitable business across Australia, New Zealand and the United States. The company has set an EBITDA improvement objective for FY27, but has not yet quantified the plan.
Sophie Babbage
Sophie Babbage
29 Sept 2026
Firebrick Pharma has approved a phased push into US retail pharmacies after Nasodine online sales grew by more than 200% in FY26. Up to six regional pharmacy groups representing about 700 stores have expressed strong interest in early orders, although no binding orders have been disclosed.
Ada Torres
Ada Torres
29 Sept 2026
First Graphene expanded its product range and international footprint in FY2026, lifting revenue while narrowing its annual loss. But the company says continued operations depend on securing further equity funding, putting commercial execution and liquidity at the centre of its next phase.
Victor Sage
Victor Sage
25 Sept 2026
PainChek grew recurring revenue, implemented licences and customer sites in FY2026, but its $8.94 million loss and $9.24 million operating cash outflow prompted an explicit going-concern warning from its auditor. The company is now betting that US deployments and a sharper commercial focus can convert market access into cash-generating growth.
Victor Sage
Victor Sage
23 Sept 2026
Emyria has presented its regulated Australian psychedelic-treatment experience to the US FDA, putting clinical delivery systems rather than drug development at the centre of its US ambitions. The appearance raises the company’s profile, but does not yet disclose regulatory approval, a commercial agreement or a financial commitment.
Ada Torres
Ada Torres
16 Sept 2026
Infratil has raised FY27 earnings guidance as data-centre demand accelerates across CDC and Longroad, with AI infrastructure now representing 73% of its NZ$22 billion asset base. The company is also sharpening its strategy around scaled growth platforms, contracted cash flows and selective new investments.
Nora Hopper
Nora Hopper
16 Sept 2026
Bubs Australia has secured permanent US FDA authorisation for three infant formula products, removing a regulatory barrier in the company’s largest market. The approval supports possible portfolio expansion and contract manufacturing, but the presentation contains no new earnings guidance or quantified financial benefit.
Victor Sage
Victor Sage
10 Sept 2026
Emyria has secured a limited in-person speaking position at a US FDA hearing examining how psychedelic medicines could be delivered safely and at scale. The appearance gives the ASX-listed company a regulatory platform, but does not represent FDA approval, funding or a commercial agreement.
Ada Torres
Ada Torres
10 Sept 2026

Browse the archive

Full archive